$TFFP reports Q4 and FY 2022 results: Exciting clinical stage programs showcased.
Mar 7th 2023, 9:18 pm
Analyst Summary: TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced their fourth quarter and full year 2022 financial results. The company’s CEO, Harlan Weisman, M.D., reported that TFF VORI and TFF TAC are the most exciting clinical stage programs in pulmonary drug delivery, and the company is expecting to announce Phase 2 proof-of-concept data for both programs in 2023. The company’s TFF technology offers the ability to transform existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits with broad applicability to most any drug. The company’s TFF platform, protected by 120+ patents, offers the potential to deliver therapies directly to the target organ, such as the lungs, allowing TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Despite the risks, TFF Pharmaceuticals’ collaboration with pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe offers potential long-term value for shareholders.